13 11 20

Information and support

  • Get informed
  • Get support
  • Cut my risk
  • Get involved
  • Research
  • P3BEP (ANZUP 1302)

    Acronym: 

    ANZUP 1302

    ACTRN/NCT /ethics: 

    NCT02582697

    Scientific title: 

    Phase 3 Accelerated BEP: A Randomised Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours

    Summary of trial and patient characteristics

    Cancer Type Other
    Trial Type Treatment
    Phase Phase III Tumour Stream Germ cell
    Age Range 11-45 years Cancer Stage Locally Recurrent or Locally Advanced
    Sex Male Anticipated Start Date 2014-02-01
    Molecular Target Anticipated End Date 2023-07-01
    Cancer Type Other
    Trial Type Treatment
    Phase Phase III
    Age Range 11-45 years
    Sex Male
    Molecular Target
    Tumour Stream Germ cell
    Cancer Stage Locally Recurrent or Locally Advanced
    Anticipated Start Date 2014-02-01
    Anticipated End Date 2023-07-01

    Trial Summary

    The purpose of this study is to determine whether accelerated BEP chemotherapy is more effective than standard BEP chemotherapy in males with intermediate and poor-risk metastatic germ cell tumours.

    Lay Summary

    Phase 3 Accelerated BEP: A Randomised Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours

    Sponsor / Cooperative group

    University of Sydney

    Participating Hospitals

    Hospital Clinical Trial Coordinator Email Phone Principal Investigator Recruitment Status
    Ashford Cancer Centre Research Helen Daykin hdaykin@adelaidecancercentre.com.au 08 8292 2240 Thean Hsing Tan Recruiting
    Flinders Medical Centre Alex Scott-Hoy alex.scott-hoy@sa.gov.au 08 8204 4830 Recruiting